PDL BioPharma (PDLI) Misses Q1 EPS by 8c, Miss on Revenues

PDL BioPharma (NASDAQ: PDLI) reported Q1 EPS of $0.01, $0.08 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.5 million versus the consensus estimate of $56.9 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
• Conduent unveils three-year growth strategy at investor day
• CarMax (KMX) PT Raised to $62 at UBS Following 'Encouraging' Q2 Print